ARID1A and ovarian carcinoma: As expected, the advantage of combining an amiR-4-expressing VSV∆51 platform and GSK126 is lost in an ARID1A-deficient ovarian cancer cell line (SKOV3)24 (Supplementary Fig. 3b).